As restrictions on kratom-derived products develop, people looking for alternatives may encounter a name that sounds familiar: 13-OH. Sellers associate it with Corydalis yanhusuo, a plant used in traditional Chinese medicine, and some include it in blends marketed to people who use 7-OH and other kratom-related substances.

For someone worried about losing access to a product they rely on for pain, sleep, or avoiding withdrawal, another botanical may seem like a practical solution. However, an herb's history does not establish the safety of a concentrated ingredient or a blend that mixes different substances.

Understanding what exactly 13-OH is, what researchers have actually studied, and what else a product contains can help you make a more informed decision about your health.

What Is 13-OH?

13-OH is a commercial label associated with Corydalis yanhusuo. Online retailers’ ingredient information commonly identifies Corydalis as 13-OH and describes combining it with kratom extract and kanna.

Corydalis yanhusuo is a flowering plant in the poppy family. Its underground tuber has a long history of use in Chinese herbal medicine. Researchers have studied several of its alkaloids, or naturally occurring chemical compounds, including tetrahydropalmatine (THP) and dehydrocorybulbine (DHCB).

The term 13-OH alone does not establish which compound is present, its concentration, or whether a finished product matches anything tested in a clinical study.

Is 13-OH An Alternative To 7-OH?

Retailers are already positioning Corydalis-containing products for people switching away from concentrated kratom-related substances. Product pages explicitly target 7-OH users and list 13-OH’s ingredients as mitragynine, Corydalis, and paraxanthine.

Federal actions have focused on specific kratom-related compounds. As of November 12, 2026, federal temporary Schedule I controls cover mitragynine pseudoindoxyl, often called pseudo, along with MGM-15 and MGM-16. The DEA's October notice proposes a revised threshold approach for 7-OH and pseudoindoxyl, with a scheduling order to be published on or after November 13. Keep in mind, a notice of intent is distinct from an effective scheduling order.

These federal actions distinguish concentrated compounds from traditional kratom and do not amount to a blanket federal kratom ban. The FDA also notes that states may have their own restrictions.

These regulatory changes may encourage interest in alternatives such as 13-OH, but availability does not establish safety or effectiveness.

Comparing 13-OH To Other Products

Similar names can make different ingredients sound interchangeable. But the distinctions matter when assessing both effects and risks.

Name What It Is Origin & Production
13-OH Commercial products featuring a Corydalis-associated ingredient, often blended with mitragynine (MIT) or kratom extract. Formulation-dependent. The marketing name alone does not establish the Corydalis ingredient’s chemical identity or whether it has been chemically modified.
Kratom Mitragyna speciosa, a plant whose leaves contain multiple alkaloids, including mitragynine. Natural botanical. Forms range from leaf powders and teas to concentrated extracts.
MIT Mitragynine, kratom’s main alkaloid. Naturally occurring. Can be extracted, concentrated, and purified from kratom. Extraction alone does not make it semi-synthetic.
7-OH 7-hydroxymitragynine, a minor alkaloid associated with kratom. Occurs at trace levels in kratom. Many concentrated products contain semi-synthetic 7-OH manufactured through chemical modification.
Pseudo Mitragynine pseudoindoxyl, a kratom-related compound with opioid activity. Products are semi-synthetic, produced by modifying kratom alkaloids.
MGM-15 Dihydro-7-hydroxymitragynine, a chemically modified derivative of 7-OH. Chemically manufactured. Semi-synthetic when produced from plant-derived starting material; also described more broadly as a synthetic derivative.


The FDA describes mitragynine and 7-OH as compounds that act at opioid receptors. A Corydalis ingredient should not automatically be assigned the same pharmacology because its marketing name also includes ‘OH’. And, adding Corydalis to a mitragynine product does not remove the risks associated with the mitragynine.

What Research Says About Corydalis Yanhusuo

Corydalis has attracted scientific interest for its potential effects on pain and other symptoms; however, the type of preparation and the study setting matter.

A controlled human study published in 2004 found that a single oral dose of Corydalis and Angelica dahurica extracts significantly reduced pain intensity and how bothersome participants found the pain during an experimental cold-exposure test. A separate 2014 study of DHCB found pain-relieving effects in mice, with dopamine receptors contributing to its action. Neither study tested the current retail blends marketed as 13-OH.

Researchers have also studied purified l-THP in people. In a small randomized trial involving 24 men who used cocaine, a short course was well tolerated. But it cannot establish the long-term safety of Corydalis extracts, modified ingredients, or combinations with mitragynine.

Research into a plant can be promising, but it’s still leaving important questions about commercial products unanswered.

13-OH Side Effects & Safety Concerns

There is not enough product-specific clinical evidence to give every formulation sold as 13-OH a reliable side effect profile.

The following concerns come from research on Corydalis, particular alkaloids, and other ingredients that may appear in these blends.

Sedation & Impairment

THP is a neuroactive compound, meaning it can affect the nervous system. Published poisonings involving concentrated THP-containing products have included serious neurological and cardiovascular effects. These reports involved particular preparations and exposures, including accidental ingestions by children; they do not establish the risk at a typical serving of a different product.

They do show why a plant-derived ingredient should not automatically be considered harmless. Avoid driving or operating machinery if a product causes sleepiness, dizziness, confusion, or impaired coordination.

Liver Injury

A 2023 report described suspected liver injury in two adults using a sleep aid containing Corydalis and cannabis. Liver tests improved after the supplement was stopped. In one patient, abnormalities returned after restarting it.

Because the product contained multiple ingredients and only two cases were reported, the study cannot establish how frequently liver injury occurs or predict the risk from every 13-OH product. It nevertheless raises a safety concern. Yellowing of the skin or eyes, dark urine, persistent nausea, or unusual fatigue warrants prompt medical evaluation.

Other Ingredients & Drug Interactions

A blend's effects cannot be judged from the Corydalis ingredient alone. Products may also contain mitragynine, kanna, or stimulants. The safety of the exact combination needs to be considered, especially alongside prescription medications or other substances.

Avoid combining these products with alcohol, opioids, benzodiazepines, or sleep medications without medical guidance. As the FDA explains, supplements can interact with medicines, and being sold as a supplement does not mean a product has received FDA approval for safety and effectiveness.

Variable Alkaloid Content

Product consistency is another concern. In a 2025 analysis of 14 Corydalis dietary supplements, researchers found substantial differences in alkaloid content, including an unusually high amount of THP in one product.

The study evaluated Corydalis supplements, not the current category of 13-OH blends. Its findings still illustrate why the same botanical name does not guarantee the same chemical exposure. A laboratory report may help clarify what a batch contains, but it does not replace human research on that formulation's safety.

Is 13-OH Addictive?

The dependence, addiction, and withdrawal risks of ingredients marketed specifically as 13-OH are not well established. It would be inaccurate to assume that Corydalis causes the same withdrawal symptoms as kratom or 7-OH. It would also be reckless to say that every product carrying this label is non-addictive.

If a 13-OH blend contains mitragynine, the risks associated with kratom remain relevant. Regular kratom use can lead to physical dependence, and switching to another mitragynine-containing formula may continue that cycle.

Can Corydalis Help With Withdrawal?

Some studies have explored Corydalis alkaloids in addiction treatment. A 2008 pilot trial involving 120 people with heroin dependence studied purified l-THP in a monitored setting and reported improvements in prolonged withdrawal symptoms and craving.

That study did not test retail 13-OH products, Corydalis-mitragynine blends, or treatment for kratom withdrawal. It does not establish that a supplement can safely replace medical withdrawal care.

If you are taking a substance mainly to avoid feeling sick, a medical provider can help assess whether you have developed physical dependence and discuss treatment options. No established dose conversion makes an unfamiliar botanical blend equivalent to the substance you were previously using.

When To Seek Help If You’re Struggling

Consider speaking with a medical provider if you need increasing amounts of a substance, experience withdrawal symptoms between doses, or repeatedly find it difficult to reduce or stop your use. Bring the packaging, ingredient list, and any available laboratory report so the provider can better understand what you have been taking.

If someone is difficult to wake, has slow or abnormal breathing, or collapses after taking a product, call 911 immediately.

Outpatient Detox At The Coleman Institute

The Coleman Institute has been helping people stop using kratom and other opioid-related substances for over 25 years. With a 95% completion rate, our outpatient kratom detox program generally takes five days. We use an abstinence-based approach with non-addictive comfort medications to help manage withdrawal symptoms.

Our medical team conducts a comprehensive assessment to determine whether outpatient detox is the right next step in your recovery journey. This also allows us to create an individualized care plan, tailored to your unique needs.

Discuss your withdrawal concerns and understand your treatment options with a recovery expert. Call 877-773-3869 for a free, confidential consultation! This article is for educational purposes only and is not a substitute for medical advice, diagnosis, or treatment. Do not begin, change, or stop any medication without guidance from a qualified healthcare provider.